文献速递胸部肿瘤

静脉注射阿米万他单抗预防输液相关反应:SKIPPirr 2期研究的简报

Preventing Infusion-Related Reactions With Intravenous Amivantamab-Results From SKIPPirr, a Phase 2 Study: A Brief Report.
PubMed 文献 · J Thorac Oncol · 2025-01-24

SKIPPirr 2期研究评估四种预防方案对静脉注射阿米万他单抗联合口服拉泽替尼治疗EGFR突变晚期非小细胞肺癌患者输液相关反应(IRR)的影响,口服地塞米松8 mg方案使C1D1 IRR发生率降至22.5%(9/40),较历史数据67.4%约降低三倍,安全性与疗效与既往报告一致。

要点

  • 口服地塞米松8 mg方案通过两阶段设计并进入扩展阶段,C1D1 IRR发生率为22.5%(9/40)。
  • 该方案使C1D1 IRR发生率较历史数据67.4%约降低三倍。
  • 截至C3结束,地塞米松8 mg队列IRR发生率为24.4%(10/41),除1例3级外均为1-2级。

核心结论

  • 口服地塞米松8 mg预防可显著降低IRR,且可方便地应用于临床实践。

研究设计与样本

  • 2期SKIPPirr研究(NCT05663866)纳入既往奥希替尼和含铂化疗进展的EGFR突变(19外显子缺失或21外显子L858R)晚期非小细胞肺癌患者,接受静脉阿米万他单抗联合口服拉泽替尼治疗。
  • 采用Simon两阶段设计评估四种独立预防方案,若队列通过两阶段则进入扩展阶段,主要终点为C1D1 IRR发生率。

主要发现

  • 截至2024年6月24日,所有队列共治疗68例参与者。
  • 地塞米松8 mg队列通过第1和第2阶段并进入扩展阶段,额外治疗24例参与者。
  • C1D1时,40例参与者中9例(22.5%)发生IRR,较历史数据67.4%约降低三倍。
  • 截至C3结束,地塞米松8 mg队列41例参与者中10例(24.4%)发生IRR,除C2D1的1例3级外均为1-2级。
  • 阿米万他单抗-拉泽替尼的安全性和疗效与既往报告一致。

关键数值与推荐

  • 口服地塞米松4 mg每日两次,于第1周期第-1天给药(共两剂)。
  • 口服地塞米松8 mg每日两次,于第1周期第-2天、第-1天及第1天早晨给药(共五剂)。
  • 口服孟鲁司特10 mg每日一次,于第1周期第-4天、第-3天、第-2天、第-1天及第1天给药(共五剂)。
  • 皮下注射甲氨蝶呤25 mg(单剂),于第1周期第-7天至第-3天之间任意时间给药。

临床怎么用

  • 口服地塞米松8 mg预防可显著降低IRR,且可方便地应用于临床实践。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Amivantamab, an EGFR-MET bispecific antibody, is approved for multiple indications in EGFR-mutated advanced NSCLC as monotherapy or combined with other agents. Intravenous amivantamab is associated with a 67% infusion-related reaction (IRR) rate. METHODS: The phase 2 SKIPPirr study (NCT05663866) enrolled participants with EGFR-mutated (exon 19 deletion or exon 21 L858R) advanced NSCLC after progression on osimertinib and platinum-based chemotherapy who received intravenous amivantamab plus oral lazertinib (amivantamab-lazertinib), a third-generation tyrosine kinase inhibitor. Aiming to mitigate IRRs, four independent prophylactic approaches were evaluated using Simon's two-stage design with an expansion stage if a cohort passed both stages: oral dexamethasone 4 mg twice daily given on cycle (C) 1 day (D) -1 (two doses); oral dexamethasone 8 mg twice daily given on C1D-2, C1D-1, and the morning of C1D1 (five doses); oral montelukast 10 mg once daily given on C1D-4, C1D-3, C1D-2, C1D-1, and C1D1 (five doses); subcutaneous methotrexate 25 mg (one dose) given anytime between C1D-7 and C1D-3. The primary end point was C1D1 IRR incidence. RESULTS: As of June 24, 2024, 68 participants were treated across all cohorts. The dexamethasone 8 mg cohort passed stages 1 and 2 proceeding to the expansion stage, with 24 additional participants treated. At C1D1, nine of 40 participants (22.5%) experienced IRRs, resulting in an approximately threefold decrease versus historical data (67.4%). By the end of C3, 10 of 41 participants (24.4%) in the dexamethasone 8 mg cohort experienced IRRs (grades 1-2, except one grade 3 on C2D1). Amivantamab-lazertinib's safety and efficacy were consistent with previous reports. CONCLUSIONS: Prophylaxis with 8 mg oral dexamethasone meaningfully reduced IRRs and can be readily implemented in clinical practice.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Spira AI, Paz-Ares L, Han JY, et al. Preventing Infusion-Related Reactions With Intravenous Amivantamab-Results From SKIPPirr, a Phase 2 Study: A Brief Report. J Thorac Oncol. 2025. PMID: 39864547. doi:10.1016/j.jtho.2025.01.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。